Haemonetics
279 hedge funds and large institutions have $5.07B invested in Haemonetics in 2018 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 94 increasing their positions, 99 reducing their positions, and 56 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 99
1.66% less ownership
Funds ownership: 100.06% → 98.39% (-1.7%)
4% less funds holding
Funds holding: 292 → 279 (-13)
14% less capital invested
Capital invested by funds: $5.92B → $5.07B (-$856M)
20% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 56
65% less call options, than puts
Call options by funds: $810K | Put options by funds: $2.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$84.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$83.7M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$44.2M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$44.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$26.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$69.1M |
| 2 |
Man Group
London,
United Kingdom
|
-$50.5M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$48.8M |
| 4 |
JP Morgan Chase
New York
|
-$45M |
| 5 |
CRCP
Copper Rock Capital Partners
Boston,
Massachusetts
|
-$31.9M |
HAE Hedge Fund Activity: Q4 2018 in Review
279 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2018, worth a combined $5.07B — down 14% from $5.92B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of HAE and 45 opened new positions — a net loss of 11 holders — while 99 trimmed existing stakes and 94 added.
The largest buyer was HealthCor Management, adding an estimated $84.1M. The largest seller was Deutsche Bank, cutting an estimated $69.1M.
- 279 institutional investors held Haemonetics (HAE) as of Q4 2018, down from 292 in Q3 2018.
- Funds reported $5.07B of Haemonetics stock for Q4 2018, down 14% quarter-over-quarter.
- 45 funds opened new Haemonetics positions in Q4 2018 and 56 closed out, a net change of -11 holders.
- The largest Haemonetics buyer in Q4 2018 was HealthCor Management, an estimated $84.1M added.
- The largest Haemonetics seller in Q4 2018 was Deutsche Bank, an estimated $69.1M sold.
Based on aggregated 13F filings for Q4 2018.